Drugs / KHK4563
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01412736 | Aug 2011 → Jul 2013 | asthma | Kyowa Kirin, Inc. | Completed | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2016-10-28 | Kyowa Kirin, Inc. | Kyowa Hakko Kirin Announces AstraZeneca Has Exercised the Exclusive Option for Commercialization of Benralizumab (KHK4563) in Japan kyowakirin.com ↗ |
| 2015-07-28 | Kyowa Kirin, Inc. | Kyowa Hakko Kirin initiated a Pivotal Phase 3 Trial of Benralizumab (KHK4563) for COPD in Japan kyowakirin.com ↗ |
| 2015-07-16 | Kyowa Kirin, Inc. | Kyowa Hakko Kirin Enters Option Agreement with AstraZeneca for Commercialisation of Benralizumab (KHK4563) in Japan kyowakirin.com ↗ |
| 2014-04-16 | Kyowa Kirin, Inc. | Kyowa Hakko Kirin initiated a Pivotal Phase 3 Trial of Benralizumab (KHK4563) for Severe Asthma in Japan kyowakirin.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KHK4563 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01412736 ↗ |
| Route | Subcutaneous | “multiple-dose subcutaneous administration of KHK4563” NCT01412736 ↗ |